# US 2024/0238456 A1 · Self-assembled biocompatible imaging particles, their synthesis and their use in imaging techniques

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0238456 A1
- Document ID: US20240238456A1
- Status: Published application
- Kind: A1
- Application number: 18/291,677
- Filed: 2022-07-29
- Published: 2024-07-18
- Earliest claimed: 2021-07-30
- Assignees: Institut National de la Sante et de la Recherche Medicale; Universite De Caen Normandie; Centre Hospitalier Universitaire De Caen Normandie
- Applicants: Institut National De La Santé Et De La Recherche MéDicale; Universite De Caen Normandie; Centre Hospitalier Universitaire De Caen Normandie
- Inventors: Maxime GAUBERTI; Sara MARTINEZ DE LIZARRONDO; Thomas BONNARD; Charlène JACQMARCQ; Denis VIVIEN
- Web page: https://patentgrep.com/patent/US20240238456A1

## CPC

- A61K 49/1857: {the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA}
- A61K 49/16: Antibodies; Immunoglobulins; Fragments thereof
- A61K 49/1887: {Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a biocompatible particle comprising nanoparticles of iron oxide embedded in a polycathecolamine or polyserotonine matrix, a suspension of said particles, a process for preparing said suspension of particles, a conjugate comprising said particle and the use of said particle and said conjugate in imaging techniques.

## Claims

### Claim 1

A particle having a hydrodynamic diameter comprised between 200 and 2000 nm, said particle comprising ultrasmall particles of iron oxide having a diameter between 1 and 50 nm embedded within a polymer matrix selected from polycathecolamines or polyserotonine.

### Claim 2 (depends on 1)

The particle according to claim 1, wherein the iron oxide is selected from Fe2O3, Fe3O4, or a mixture of Fe2O3 and Fe3O4.

### Claim 3 (depends on 1)

The particle according to claim 1, wherein the polymer matrix is from polydopamine (PDA), polynorepinephrine (PNE), polyepinephrine (PEP) and polyserotonine.

### Claim 4 (depends on 1)

The particle according to claim 1, wherein the iron concentration is comprised between 50% and 95% in weight with respect to the to total weight of the particle.

### Claim 5 (depends on 1)

A suspension of particles according to claim 1.

### Claim 6 (depends on 5)

A process for preparing a suspension of particles according to claim 5, comprising the steps of:
a) Preparing a suspension of ultrasmall particles of iron oxide having a diameter between 1 and 50 nm;
b) Coating of the ultrasmall particles of iron oxide with a catecholamine or serotonine;
c) Polymerizing the catecholamine or serotonine in the presence of the ultrasmall particles of iron oxide,
d) Terminating said polymerization; and
e) Recovering a suspension of particles.

### Claim 7 (depends on 6)

Suspension of particles or particle obtained by the process according to claim 6.

### Claim 8 (depends on 1)

Conjugate comprising a particle according to claim 1 and a molecule comprising free amine or thiol groups.

### Claim 9 (depends on 8)

Conjugate according to claim 8, wherein the molecule comprising free amine or thiol groups is chosen from a protein, a peptide, a nanobody, a monoclonal antibody or a molecule comprising a radiolabeled metal.

### Claim 10 (depends on 9)

Conjugate according to claim 9, wherein the monoclonal antibody is chosen from vascular-cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), P-Selectin, E-Selectin or mucosal addressin cell adhesion molecule 1 (MAdCAM-1).

### Claim 11 (depends on 1)

An in vivo method of imaging comprising the step of administering to a patient an effective amount of the particle according to claim 1.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the method of imaging is selected from Magnetic Resonance Imaging (MRI), Magnetic Particle Imaging (MPI), photoacoustic imaging and Positron Emission Tomography (PET).

### Claim 13 (depends on 5)

A composition comprising a suspension of particles according to claim 5.

### Claim 14 (depends on 13)

A method of imaging, comprising the step of administering to a patient an effective amount of the composition of claim 13 and an imaging step.

### Claim 15

(canceled)

### Claim 16 (depends on 8)

Conjugate according to claim 8, wherein the molecule comprising free amine or thiol groups is a monoclonal antibody.

### Claim 17 (depends on 8)

Conjugate according to claim 8, wherein the molecule comprising free amine or thiol groups is a protein that can be a tissue plasminogen activator (tPA) or a fragment thereof.

### Claim 18 (depends on 8)

Conjugate according to claim 8, wherein the molecule comprising free amine or thiol groups is a recombinant tissue plasminogen activator (rtPA).

### Claim 19 (depends on 8)

Conjugate according to claim 8, wherein the molecule comprising free amine or thiol groups is alteplase, reteplase or tenecteplase.

### Claim 20 (depends on 5)

Conjugate comprising a suspension of particles according to claim 5 and a molecule comprising free amine or thiol groups.

### Claim 21 (depends on 8)

An in vivo method of imaging comprising the step of administering to a patient an effective amount of the conjugate according to claim 8 and an imaging step.
